These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21649822)

  • 1. Phosphatidylcholine/deoxycholate lipolysis and hyaluronic acid augmentation to enhance nonsurgical lower facial contouring using botulinum toxin type A.
    Wong GR; Chen WP
    J Cosmet Dermatol; 2011 Jun; 10(2):159-62. PubMed ID: 21649822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
    Baş B; Ozan B; Muğlali M; Celebi N
    Med Oral Patol Oral Cir Bucal; 2010 Jul; 15(4):e649-52. PubMed ID: 20173718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facial Contouring With Fillers, Neuromodulators, and Lipolysis to Achieve a Natural Look in Patients With Facial Fullness.
    Anand C
    J Drugs Dermatol; 2016 Dec; 15(12):1536-1542. PubMed ID: 28095576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width.
    Wu WT
    Facial Plast Surg Clin North Am; 2010 Feb; 18(1):133-40. PubMed ID: 20206096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to achieve synergy between volume replacement and filling products for global facial rejuvenation.
    Raspaldo H; Aziza R; Belhaouari L; Berros P; Body S; Galatoire O; Le Louarn C; Michaud T; Niforos F; Rousseaux I; Runge M; Taieb M
    J Cosmet Laser Ther; 2011 Apr; 13(2):77-86. PubMed ID: 21401381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global 3-dimensional approach to natural rejuvenation: recommendations for perioral, nose, and ear rejuvenation.
    Gassia V; Raspaldo H; Niforos FR; Michaud T
    J Cosmet Dermatol; 2013 Jun; 12(2):123-36. PubMed ID: 23725306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy.
    Arikan OK; Tan FU; Kendi T; Koc C
    J Otolaryngol; 2006 Feb; 35(1):40-3. PubMed ID: 16527016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin for masseter hypertrophy.
    Al-Muharraqi MA; Fedorowicz Z; Al Bareeq J; Al Bareeq R; Nasser M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007510. PubMed ID: 19160335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring facial symmetry through non-surgical cosmetic procedures after permanent facial paralysis: a case report.
    Sahan A; Tamer F
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):41-42. PubMed ID: 28632885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The medical management of masseteric hypertrophy with botulinum toxin.
    Finn S; Ryan P; Sleeman D
    J Ir Dent Assoc; 2000; 46(3):84-6. PubMed ID: 11323940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin for masseter hypertrophy.
    Fedorowicz Z; van Zuuren EJ; Schoones J
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD007510. PubMed ID: 24018587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of botulinum toxin type A in aesthetic mandibular contouring.
    Kim NH; Chung JH; Park RH; Park JB
    Plast Reconstr Surg; 2005 Mar; 115(3):919-30. PubMed ID: 15731696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for masseter reduction in Asian patients.
    Ahn J; Horn C; Blitzer A
    Arch Facial Plast Surg; 2004; 6(3):188-91. PubMed ID: 15148129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin in facial rejuvenation: an update.
    Carruthers J; Carruthers A
    Dermatol Clin; 2009 Oct; 27(4):417-25, v. PubMed ID: 19850191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.